These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 16518379)

  • 1. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaptanib for wet macular degeneration.
    Fraunfelder FW
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegaptanib sodium for the treatment of age-related macular degeneration.
    Apte RS
    Expert Opin Pharmacother; 2008 Feb; 9(3):499-508. PubMed ID: 18220500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegaptanib sodium for ocular vascular disease.
    Shukla D; Namperumalsamy P; Goldbaum M; Cunningham ET
    Indian J Ophthalmol; 2007; 55(6):427-30. PubMed ID: 17951898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: pegaptanib, Eyetech/Pfizer.
    Vinores SA
    Curr Opin Mol Ther; 2003 Dec; 5(6):673-9. PubMed ID: 14755895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
    Ng EW; Adamis AP
    Ann N Y Acad Sci; 2006 Oct; 1082():151-71. PubMed ID: 17145936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jul; 6(8):1421-3. PubMed ID: 16013991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
    Ng EW; Adamis AP
    Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
    Starita C; Patel M; Katz B; Adamis AP
    Dev Ophthalmol; 2007; 39():122-148. PubMed ID: 17245083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
    Morjaria R; Chong NV
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B; Wang B
    Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development.
    Amadio M; Govoni S; Pascale A
    Pharmacol Res; 2016 Jan; 103():253-69. PubMed ID: 26678602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
    Andrade N; Crispim Ribeiro J; Araújo E Silva PM; Savio D; Fechine FV; de Moraes MO
    J Ocul Pharmacol Ther; 2021 Jun; 37(5):277-283. PubMed ID: 33891495
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
    Ju M; Mailhos C; Bradley J; Dowie T; Ganley M; Cook G; Calias P; Lange N; Adamis AP; Shima DT; Robinson GS
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
    Katz B; Goldbaum M
    Int Ophthalmol Clin; 2006; 46(4):141-54. PubMed ID: 17060800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.